No Data
East Sun Pharmaceutical (01875.HK): A breakthrough player in the ADC market, can the international quality system unlock profit growth?
When the market anchors the valuation of the CDMO Industry in terms of scale and profitability, Dongyao Pharmaceutical is building a little-known "hidden value growth curve" – establishing a globally leading capacity and quality management system to create global Business capabilities and harvest more opportunities for Business development. 1. The overlooked trump card: establishing a competitive moat with an international standard quality system. In the Capital Markets' conventional understanding of CDMO enterprises, capacity scale and cost advantages are often seen as core valuation factors. However, the latest annual report from Dongyao Pharmaceutical reveals that a more strategically profound plan is unfolding around it.
TOT BIOPHARM-B (01875.HK): Sun Hui, Zhang Qian, and Gu Xuelin have each been appointed as independent non-executive Directors.
Gelonghui, March 12, regarding TOT BIOPHARM-B (01875.HK), announced that effective from March 12, 2025: (i) Hu Lan has resigned from the position of independent non-executive director, chairman of the audit and related party transaction review committee, and member of the nomination committee due to the expiration of his three-year term and his desire to devote more time to other matters; (ii) Zhang Hongren has resigned from the position of independent non-executive director, member of the audit and related party transaction review committee, and member of the remuneration committee due to the expiration of his three-year term and his desire to devote more time to other matters; (iii) Wang Deqian due to the expiration of the three-year term.
TOT Biopharm Turns to Yearly Profit for First Time in 2024 as Revenue Soars 41%; Shares Down 3%
TOT BIOPHARM-B (01875) is projected to surpass 1 billion yuan in revenue in 2024, achieving annual profitability for the first time, with a net profit reaching 34.757 million yuan.
TOT BIOPHARM-B (01875) announced its 2024 results, exceeding expectations, with annual revenue exceeding 1 billion, reaching...
Express News | TOT BIOPHARM International FY Cash Flow From Operating Activities RMB 116.403 Million
Express News | TOT BIOPHARM International FY Net Income RMB -34.757 Million
